Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 264 matching trials from the live ClinicalTrials.gov search.
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, FLU HD vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
1,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
46
States / cities
Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more
Conditions
Healthy
Interventions
Motavizumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
0 Months to 6 Months
Enrollment
2,127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
12
States / cities
Chinle, Arizona • Cibecue, Arizona • Fort Definace, Arizona + 9 more
Conditions
Drug Safety
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Conditions
RSV Infection
Interventions
EDP-938, Itraconazole, Rifampin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA BN RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

MVA-BN-RSV Vaccine Trial

NCT05238025
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
60 Years and older
Enrollment
20,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
105
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 23 Months
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
6
States / cities
Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
Conditions
Adult, Healthy Participants
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Lake Forest, California • Riverside, California + 11 more
Conditions
Healthy
Interventions
IVX-A12, Placebo
Biological
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
10
States / cities
Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Airway Obstruction in Infants With Lower Respiratory Infections

NCT00435994
Conditions
Bronchiolitis, Respiratory Syncytial Virus Infections
Interventions
Inhaled primatene will be given as a breathing treatment, Nasal Washing
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 2 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Infection
Interventions
ribavirin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • St Louis, Missouri + 1 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
770 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more
Conditions
Respiratory Distress Syndrome, Adult, Respiratory Syncytial Virus Infections, Pneumonia, Acute Lung Injury
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
1 Hour and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV ΔNS2/Δ1313/I1314L, RSV 276, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
Conditions
RSV Bronchiolitis
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Month to 18 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Respiratory Syncytial Virus Infection Prevention
Interventions
Ad26.RSV.preF-based Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
Conditions
Respiratory Syncytial Virus Infections, Virus Diseases
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
1 Month to 24 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kirksville, Missouri
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
10,212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
56
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

NCT06134648
Conditions
Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions
RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
60 Years and older
Enrollment
36,814 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
133
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more
Conditions
RSV Infection
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 30 more